There is growing evidence that mTOR inhibitors in multi-drug combination regimens can overcome the largely cytostatic effect of mTOR inhibitor monotherapies thus leading to improved treatment outcomes especially in advanced cancers. The gene discussed is MTOR; the disease is cancer.